Cost-Containment

The DOL's complaint against BCBSM, Inc., as well as the series of lawsuits against other TPAs and insurers, may redefine the landscape of fiduciary responsibilities and the role of TPAs in plan administration.

On Feb. 1, the CMS will send its initial offer of a fair price for each of the 10 selected prescription drugs to the drugmakers, who have all filed lawsuits attempting to block the government's effort to control drug prices.

Racial and ethnic earning disparities associated with health insurance premium growth have increased over time.

Plan sponsors must evaluate their current PBM arrangements and decide whether they have a transparent arrangement that they trust or if there is a need to re-evaluate the PBM relationship.

President Trump secured significant health care policy changes still in place today, including efforts to bring more transparency to prices charged by hospitals and paid by insurers, but he still wants to repeal and replace the ACA.

A look at new legal battles and drug regulations, including the administration's new initiatives to reduce drug costs and next steps in the FTC's attempt to address improperly listed patents in the FDA's Orange Book.